Skip to main content
Thorax logoLink to Thorax
. 1995 Dec;50(12):1321–1323. doi: 10.1136/thx.50.12.1321

Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema.

I F Purcell 1, P A Corris 1
PMCID: PMC1021361  PMID: 8553311

Abstract

A 28 year old man with asthma, bronchopulmonary aspergillosis, pulmonary thromboembolic disease, and pulmonary hypertension developed Aspergillus fumigatus empyema complicating a pneumothorax. His condition progressively deteriorated despite treatment with intravenous and intrapleural amphotericin B, but improved promptly after substituting nebulised liposomal amphotericin B and oral itraconazole. This experience suggests that nebulised liposomal amphotericin B is well tolerated and merits further assessment in the treatment of pulmonary fungal disease.

Full text

PDF
1321

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chopra R., Blair S., Strang J., Cervi P., Patterson K. G., Goldstone A. H. Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients. J Antimicrob Chemother. 1991 Oct;28 (Suppl B):93–104. doi: 10.1093/jac/28.suppl_b.93. [DOI] [PubMed] [Google Scholar]
  2. Denning D. W., Stevens D. A. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis. 1990 Nov-Dec;12(6):1147–1201. doi: 10.1093/clinids/12.6.1147. [DOI] [PubMed] [Google Scholar]
  3. Ellis D. A., Neville E., Hall R. J. Subacute massive pulmonary embolism treated with plasminogen and streptokinase. Thorax. 1983 Dec;38(12):903–907. doi: 10.1136/thx.38.12.903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Lopez-Berestein G., Bodey G. P., Fainstein V., Keating M., Frankel L. S., Zeluff B., Gentry L., Mehta K. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med. 1989 Nov;149(11):2533–2536. [PubMed] [Google Scholar]
  5. Meunier F., Prentice H. G., Ringdén O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother. 1991 Oct;28 (Suppl B):83–91. doi: 10.1093/jac/28.suppl_b.83. [DOI] [PubMed] [Google Scholar]
  6. Ringdén O., Meunier F., Tollemar J., Ricci P., Tura S., Kuse E., Viviani M. A., Gorin N. C., Klastersky J., Fenaux P. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother. 1991 Oct;28 (Suppl B):73–82. doi: 10.1093/jac/28.suppl_b.73. [DOI] [PubMed] [Google Scholar]
  7. Taylor K. M., Newton J. M. Liposomes for controlled delivery of drugs to the lung. Thorax. 1992 Apr;47(4):257–259. doi: 10.1136/thx.47.4.257. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES